HLS Therapeutics Inc.
HLTRF
$2.72
$0.082.96%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.54% | 1.91% | -2.23% | -4.08% | -2.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.54% | 1.91% | -2.23% | -4.08% | -2.40% |
| Cost of Revenue | 17.72% | 9.29% | 1.25% | 3.67% | 3.98% |
| Gross Profit | -1.79% | -1.31% | -3.53% | -6.81% | -4.59% |
| SG&A Expenses | 2.70% | -4.75% | -15.62% | -18.11% | -19.67% |
| Depreciation & Amortization | 0.78% | 3.28% | 0.53% | 0.05% | -6.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.89% | 1.79% | -5.58% | -6.84% | -9.64% |
| Operating Income | -48.59% | -1.10% | 179.00% | 27.42% | 61.58% |
| Income Before Tax | 59.70% | 48.53% | 32.54% | 19.74% | -55.60% |
| Income Tax Expenses | -94.63% | 108.70% | -861.18% | 71.19% | -94.06% |
| Earnings from Continuing Operations | 62.79% | 48.22% | 55.84% | 19.12% | 51.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.79% | 48.22% | 55.84% | 19.12% | 51.76% |
| EBIT | -48.59% | -1.10% | 179.00% | 27.42% | 61.58% |
| EBITDA | -7.12% | 4.80% | 11.25% | 14.44% | 22.81% |
| EPS Basic | 62.36% | 47.38% | 60.00% | 18.11% | 51.65% |
| Normalized Basic EPS | 59.31% | 47.66% | 38.88% | 18.44% | 49.75% |
| EPS Diluted | 63.78% | 47.57% | 61.94% | 18.11% | 50.00% |
| Normalized Diluted EPS | 59.31% | 47.66% | 38.88% | 18.44% | 49.75% |
| Average Basic Shares Outstanding | -1.16% | -1.63% | 10.40% | -1.23% | -0.24% |
| Average Diluted Shares Outstanding | -1.16% | -1.63% | 10.40% | -1.23% | -0.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |